Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
necitumumab + mFOLFOX-6
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Necitumumab + mFOLFOX-6** is a combination regimen consisting of **necitumumab**, a recombinant human IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), combined with **modified FOLFOX-6 (mFOLFOX-6)**. mFOLFOX-6 is a chemotherapy protocol containing oxaliplatin, leucovorin (folinic acid), and fluorouracil (5-FU), widely used for gastrointestinal and colorectal cancers. Necitumumab acts by binding and inhibiting EGFR, interfering with downstream signaling pathways important for tumor cell proliferation and survival. mFOLFOX-6 acts as cytotoxic chemotherapy targeting rapidly dividing cancer cells through DNA crosslinking (oxaliplatin) and inhibition of DNA and RNA synthesis (5-FU, modulated by folinic acid). The combination is under clinical investigation for advanced solid tumors such as metastatic colorectal cancer.
- Other names
- necitumumab plus mFOLFOX-6mFOLFOX6 plus necitumumabmFOLFOX-6 plus necitumumabmFOLFOX 6 plus necitumumab
02
Targets
Beyond the preview
Go deeper on necitumumab + mFOLFOX-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on necitumumab + mFOLFOX-6.